The effects of MDR-1 gene polymorphisms on the clinical course of chronic hepatitis B infection

dc.authorid0000-0001-5008-6576
dc.authorid0000-0002-1941-3935
dc.authorid0000-0003-0290-8787
dc.authorid0000-0003-3136-0191
dc.authorid0000-0001-6009-1256
dc.contributor.authorŞıvgın, Hakan
dc.contributor.authorYılmaz, Abdülkerim
dc.contributor.authorRüstemoğlu, Aydın
dc.contributor.authorÖztürk, Banu
dc.contributor.authorŞahin, Şafak
dc.contributor.authorTaşlıyurt, Türker
dc.date.accessioned2025-07-31T05:15:15Z
dc.date.available2025-07-31T05:15:15Z
dc.date.issued2023
dc.departmentTıp Fakültesi
dc.description.abstractChronic HBV infection is associated with a high morbidity and mortality rate due to the increased risk of hepatic cirrhosis and hepatocellular cancer. Treatment modalities and resistance are currently being investigated. Several mechanisms underlie drug resistance. P-glycoprotein (P-gp), the product of the multidrug resistance gene (MDR-1), is a well-known mechanism of the MDR phenotype. MDR gene C1236T polymorphism is associated with decreased p-gp function. The mutation of the MDR gene can affect the clinical course of the disease and response rate to treatment. The aim of our study was to investigate the relationship between MDR gene polymorphism and clinical course and treatment responses in chronic HBV infection. Methods: A total of 90 (male∕female: 69/21) patients with chronic HBV infection under Lamivudine treatment were enrolled in this study. Mean ages were 49.8±12.6 (range: 22-75) years. The patients were categorized as: Treatment-respondent (group 1: HBV-DNA is negative at the 24th week) and treatment-refractory (group 2: HBV-DNA is still positive after the 24th week). Group 1 consisted of 51 (M/F: 38/13) and group 2 consisted of 39 (M∕F: 31∕9) patients. There was no significant difference between the ages and genders of the two groups. Histologic activity indexes (HAI), total bilirubin, AST and ALT levels, and HBV-DNA titers were significantly higher in the patients in group 2 than in group 1 (p<0.05).
dc.identifier.doi10.51271/KMJ-0086
dc.identifier.endpage5
dc.identifier.issn2757-9336
dc.identifier.issue1
dc.identifier.startpage1
dc.identifier.urihttps://dx.doi.org/10.51271/KMJ-0086
dc.identifier.urihttps://hdl.handle.net/20.500.12451/13673
dc.identifier.volume3
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorRüstemoğlu, Aydın
dc.institutionauthorid0000-0002-1354-4598
dc.language.isoen
dc.publisherMediHealth Academy Yayıncılık
dc.relation.ispartofKastamonu Medical Journal (KASMEJ)
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHepatitis B
dc.subjectLamivudine Resistance
dc.subjectMDR-1 Gene Polymorphism
dc.titleThe effects of MDR-1 gene polymorphisms on the clinical course of chronic hepatitis B infection
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
sivgin-hakan-2023.pdf
Boyut:
3.66 MB
Biçim:
Adobe Portable Document Format
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: